Alex Hoffman / endpoints - → In what appears to be another blow to Novo Nordisk, ex-Pfizer CSO Mikael Dolsten has withdrawn his nomination to join the company's board of directors due to ...
#healthcare #pharmaceuticals #publichealth #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment
Saturday, November 15, 2025, 3:21 pm / permalink 16003 / 2 stories in 4 months
Roni Caryn Rabin / nytimes - The benefits of hormone replacement have been underappreciated, Dr. Marty Makary, the agency’s commissioner, said on Monday. Critics described evidence for the change as insufficient.
#healthcare #pharmaceuticals #publichealth #governmentpolicy #fda
Saturday, November 15, 2025, 10:21 am / permalink 15996 / 3 stories in 4 months
go - The Food and Drug Administration is adding a new warning to a gene therapy linked to two patient deaths earlier this year
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda
Saturday, November 15, 2025, 5:21 am / permalink 15991 / 3 stories in 4 months
oncodaily - Traces of bacteria inside brain tumors may affect tumor behavior Researchers found bacterial genetic and cellular elements inside brain tumor cells that appear biologically active and may influence tumor progression […]
#healthcare #publichealth #biotech #drugdevelopment
Saturday, November 15, 2025, 2:20 am / permalink 15988 / 2 stories in 4 months
go - Researchers are reporting what they believe is the first documented death from a meat allergy triggered by tick bites
Saturday, November 15, 2025, 1:21 am / permalink 15987 / 3 stories in 4 months
medicalxpress - Health officials in Washington state say they have identified the nation's first human case of bird flu since February, pending confirmatory testing.
Saturday, November 15, 2025, 12:21 am / permalink 15985 / 4 stories in 4 months
HIMSS 2026 pushes real‑time data, cloud and interoperability playbook 14 stories in 18.3 hours
Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma 3 stories in 19.3 hours
Vitamin D trial shows reduced long‑COVID risk but no severity benefit 2 stories in 21.3 hours
Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival 4 stories in 22.3 hours
FDA approves leucovorin for rare folate disorder despite autism hype 4 stories in 34.3 hours
HORMAD1 emerges as a potential target in triple‑negative breast cancer 4 stories in 47.3 hours
Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio 2 stories in 50.3 hours
Roche’s hoped‑for breast cancer pill fails crucial first‑line trial 5 stories in 51.3 hours
Novo Nordisk and Hims bury the hatchet and carve a deal 3 stories in 56.3 hours
AI improves UK breast-screening detection by about 10% 5 stories in 56.3 hours
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.
Bluesky: